“As Washington prepares for a major international AIDS conference this summer, developments on the drug front are once again elevating the subject of the continuing epidemic in the public eye,” CQ HealthBeat reports. The article mentions an FDA panel’s recent recommendation for the approval of Truvada for pre-exposure prophylaxis (PrEP) to prevent HIV among healthy people at risk of contracting the virus and a bill (S 1138) introduced last week by Sen. Bernie Sanders (I-Vt.) aimed at reducing the cost of antiretroviral drugs (ARVs). The bill, which is focused on the cost of ARVs in the U.S., would “create a $3 billion ‘prize fund,’ through which [pharmaceutical] firms that bring a new HIV or AIDS medicine to market would get awards” in exchange for relinquishing patent rights to the drug, according to CQ (Norman, 5/18).
Private Sector Involvement
Key Player In Obama Administration's Plan To Fight Hunger In Africa Under Criminal Investigation, Blog Reports
“Last week, at the opening of the G8 conference hosted by the United States, President Barack Obama announced a $3 billion, largely private sector plan aimed at fighting hunger in Africa,” KPLU 88.5’s “Humanosphere” blog reports, adding, “Now we learn that the top player on Obama’s private sector plan to fight…
The argument that “a country’s quickest way to better health for its people is economic development … is only one factor, and not the most important one, in explaining global health outcomes,” Charles Kenny, a senior fellow at the Center for Global Development, writes in a SciDev.Net opinion piece. “The challenge is to ensure that a cheap basic package of health interventions is available to — and is used by — all,” he continues.
Obama To Announce New Initiative Aimed At Boosting African Agriculture In Advance Of G8 Summit This Weekend
On Friday, President Barack Obama is expected to announce “new investments in African agriculture in a speech in Washington … as a precursor to the weekend Group of Eight [G8] summit at Camp David, Maryland,” Bloomberg Businessweek reports (Bjerga, 5/18). “The president is scheduled to speak to African leaders at a summit on food security Friday,” VOA News writes, adding, “[The] new initiative is expected to target 50 million food-insecure people by boosting agricultural investments” (5/17). According to NPR’s “Morning Edition,” “The leaders of Tanzania, Ethiopia, and Ghana are among those in Washington to launch the new food security initiative, which [USAID Administrator Rajiv Shah] says will include several billion dollars in investments from private companies” (Kelemen, 5/18). “We are never going to end hunger in Africa without private investment,” Shah said, the New York Times writes (Strom, 5/17).
“The worldwide counterfeit drug market is huge and growing,” Tim Mackey and Brian Liang of the Institute of Health Law Studies at the California Western School of Law and Thomas Kubic of the Pharmaceutical Security Institute write in a Foreign Policy opinion piece, noting such “drugs occupy a wide spectrum of medications, and their quality is suspect; they can be mislabeled, tainted, adulterated, ineffective, or, in the worst cases, all of the above.” They argue for a new framework for fighting the illegal drug trade because “[g]lobal policy has not kept up with the burgeoning counterfeit drug trade.” The authors say that although initial results of the WHO IMPACT (International Medical Products Anti-Counterfeit Taskforce) are “encouraging,” they note that “[s]ome WHO member states, including India and Brazil (both top producers of generic drugs) and other developing countries, have questioned whether WHO can rightly take on enforcement operations” because it “is not a global law enforcement agency.”
In a post on USAID’s “IMPACTblog,” Amanda Makulec of John Snow Inc. describes the Helping Babies Breathe (HBB) initiative, which was developed “to equip birth attendants in developing countries with the skills they need to successfully resuscitate babies born without the ability to breathe on their own.” She continues, “[I]t was the power of the Global Development Alliance (GDA) model — public-private partnership on a global scale — that dramatically expanded access to newborn resuscitation in remote health facilities and communities in 34 countries within 18 months of the launch of the partnership … by leveraging the commitment, resources, and support of a diverse group of program implementers, NGOs, private sector organizations, government institutions, U.N. agencies, professional associations to enable the rapid roll out of the intervention globally” (4/30).
The Center for Global Health Policy’s “Science Speaks” blog notes that PEPFAR recently released its 8th annual report (.pdf) to Congress. “The five-page document outlines the program’s progress as of the end of fiscal year 2011 in various areas,” including the provision of antiretroviral treatment, care, and support; HIV testing and counseling for pregnant women; and prevention of mother-to-child transmission services, the blog notes. The report includes sections on “leading with science,” “smart investments,” “country ownership,” and “shared responsibility,” according to the blog (Mazzotta, 5/4).
The non-profit advocacy group Research!America on Monday released a list titled “Top 10 Reasons To Invest In Global Health R&D,” which “provides compelling reasons why the investments are critical, from the humanitarian benefits to being a powerful driver of U.S. economic activity,” according to an e-mail alert (10/15). The list’s webpage states, “The U.S. needs to strengthen its investment in this important research, not only because it saves millions of lives worldwide but because it benefits the health of Americans, spurs new businesses and jobs in the U.S., helps protect our troops on the ground, and promotes global stability and security. Federal funding for global health R&D is the smart thing to do for the U.S. and the right thing to do for the world” (10/15).
Though the number of children dying of preventable and treatable diseases worldwide has dropped significantly since 1990, there is “realistic hope for much more” progress, particularly if “[i]mproved hygiene and sanitation … play a key role in the next stage,” Jeffrey Sachs, director of the Earth Institute at Columbia University, and Paul Polman, CEO of Unilever, write in the Huffington Post’s “Global Motherhood” blog. Noting that “diarrhea and pneumonia are the two leading killers of children, accounting for almost 30 percent of under-five deaths globally,” they state, “Vaccines can help, but improved hygiene and sanitation are also vital, and therefore key to meeting the Millennium Development Goal of cutting the child mortality rate by at least two-thirds by 2015.”
The Financial Times has published a special report (.pdf) on neglected tropical diseases (NTDs) featuring 10 articles examining issues including prevention, research, and treatment.